human serum News
-
Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII
Amerigo Scientific, a distributor focused on providing critical products and services to the biomedical and life science communities, recently announced the launch of its new polyclonal antibody to human blood coagulation factor XIII to support researchers in life science fields for the detection of blood coagulation factor XIII. This antibody is used for research only, not for human, therapeutic ...
-
Amerigo Scientific Introduces the Launch of Polystreptavidin 350
Amerigo Scientific, a distribution company focused on providing critical products and services to the biomedical and life science research communities, now introduces Polystreptavidin 350 for applications in lateral flow, ELISA or CLIA. Diagnosis is a key enabler of universal health coverage and the first line of defense against the spread of many diseases. From rapid treatment and combating ...
-
Frontier Biotech partners with R-pharm to provide Aikening to Russian patients
Frontier Biotech (stock code: 688221.SH) announces that it signs an agreement with R-Pharm, JSC, one of the largest pharmaceutical companies in Russia, for registration and commercialization of Aikening® (generic name: Albuvirtide) in Russia. Cheryl Tan, Global Head of Frontier Biotech's International Businesses, said, “Aikening® is the first new long-acting antiretroviral drug ...
-
Bisphenol A exposure can increase risk of diabetes and heart attacks
In human fat tissues, bisphenol A (BPA) suppresses levels of a key hormone, adiponectin, that protects people from heart attacks and Type II diabetes. These results implicate BPA as a potential cause of metabolic syndrome, one of the most serious and costly public health problems in the US. Most Americans have levels of BPA within their serum within the range of concentrations sufficient to ...
-
Abbott receives FDA approval for first fully automated blood test for `kissing bug` disease
Abbott received Biologic License Application (BLA) approval from the United States Food and Drug Administration (FDA) for the ABBOTT PRISM Chagas test. The test is a fully automated blood screening assay that can detect antibodies to Trypansoma cruzi (T. cruzi), a parasite found only in the Americas and most commonly acquired through contact with the blood-sucking triatomine or "kissing bug." ...
-
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD). ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you